Anupam Rasayan India Ltd. Reports Strong Q1 FY27 with 36% Revenue Growth

Q1 FY27 Total Income: INR 668 crore (36% YoY growth)
Q1 FY27 PAT: INR 51 crore (6% YoY growth)

Reader Takeaway: Robust revenue and EBITDA growth offset by slower PAT growth due to depreciation.

What just happened

Anupam Rasayan India Ltd. announced its financial results for the first quarter of FY27, showcasing significant top-line growth. Total income rose by 36% year-on-year to INR 668 crore. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) increased by 35% to INR 175 crore, maintaining a healthy EBITDA margin of 26%. Profit After Tax (PAT) grew by 6% to INR 51 crore. Management attributed the slower PAT growth to increased depreciation from asset base expansion and the integration of Jayhawk Fine Chemicals.

Why this matters

The strong revenue and EBITDA figures indicate healthy operational performance and demand for Anupam Rasayan's products. The successful commercialization of Ethyl Trifluoroacetate (ETFA) using advanced flow chemistry, a global first, opens doors to new, high-value markets in pharmaceuticals, agrochemicals, and electronics, estimated at $0.5 billion. Furthermore, a Letter of Intent with BASQUEVOLT for a potential $300 million specialty chemical supply over 10 years signals substantial future revenue streams.

The backstory

Anupam Rasayan has been undergoing a significant expansion phase, including the acquisition of Jayhawk Fine Chemicals, which is now contributing 20-22% of revenue and serves as a key US manufacturing base. The acquisition of Bliss GVS Pharma is also progressing, with SEBI approval obtained. The company had undertaken a major capital expenditure (capex) cycle to enhance its manufacturing capabilities.

What changes now

The company has declared its major capex cycle complete, meaning significant new investments in the existing Anupam platform are not anticipated in the near term. Annual maintenance and repurposing capex are expected to be around INR 70-80 crore. The focus now shifts to scaling up operations, integrating acquisitions, and realizing the potential from new product commercializations and strategic partnerships.

Risks to watch

Investors should monitor the impact of higher depreciation and integration costs on profitability. While EBITDA growth is strong, the 6% PAT growth highlights the pressure on the bottom line. The successful integration of Bliss GVS Pharma is crucial for the company's pharmaceutical sector strategy.

Peer comparison

Anupam Rasayan operates in the specialty chemicals sector, competing with other Indian and global players focused on custom synthesis and manufacturing. Companies like Aarti Industries, Vinati Organics, and Navin Fluorine International are key players in similar segments, often distinguished by their product portfolios and technological capabilities.

Context metrics (time-bound)

• For FY27, Anupam Rasayan has guided for approximately 25% organic revenue growth.
• An additional 10-15% revenue contribution is expected from the Jayhawk revenue line in FY27.
• The BASQUEVOLT supply agreement is projected to begin commercialization in FY27.
• The Bliss GVS Pharma acquisition is expected to fully close by the first half of September 2026.

What to track next

Investors will be keen to observe the PAT margins in upcoming quarters as the impact of depreciation from expansion and integration costs normalizes. The progress of the Bliss GVS Pharma integration and the realization of revenue from the BASQUEVOLT LOI will be key performance indicators to track.